George is a molecular pharmacologist who completed his PhD in collaboration with Pfizer. He leads a research group and a university spin-out company dedicated to developing novel therapies for diseases driven by aberrant cyclic AMP signaling systems. His team addresses a wide spectrum of conditions, including prostate cancer, Huntington's disease, cardiovascular disorders, and rare diseases such as Acrodysostosis type II. Their translational research is supported by pharmaceutical companies and national government funding schemes.